ReviewNature reviews. Nephrology2026
The pathophysiology of pre-eclampsia.
Review in Nature reviews. Nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pre-eclampsia is a serious complication of pregnancy that contributes to maternal and neonatal morbidity and mortality. Maternal endothelial dysfunction, particularly in the kidney, liver and cerebral vascular beds, causes the key clinical features of hypertension and proteinuria as well as the potentially fatal complications of eclampsia: stroke, acute kidney injury and liver dysfunction. The placenta has a key role in moderating these systemic maternal responses and potentially also changes in fetal growth. As pre-eclampsia progresses, the dysfunctional placenta produces toxins that contribute to maternal endothelial dysfunction and disease development. These toxins, including the anti-angiogenic factor soluble fms-like tyrosine kinase-1 (sFLT1), can be utilized as biomarkers. Other pathophysiological contributions to placental dysfunction, including ischaemia, inflammation and senescence, as well as risk factors such as older maternal age, obesity, diabetes mellitus, chronic hypertension or multifetal gestation, may help to explain differences in disease presentation. Chronic kidney disease is a risk factor for the development of pre-eclampsia during early pregnancy, and early pre-eclampsia may reflect undiagnosed underlying kidney disease in some patients. Furthermore, pre-eclampsia is a risk factor for kidney and cardiovascular disease in the mother and baby in later life. Understanding the pathways that contribute to pre-eclampsia facilitates the development of potential prevention strategies and treatments for early-presenting disease with severe features.
Indexed as
Identifiers
42174049What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.